11/15
06:59 am
fate
Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates [Yahoo! Finance]
Medium
Report
Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates [Yahoo! Finance]
11/14
06:59 am
fate
Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/13
08:06 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
High
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/13
12:45 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
High
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
11/12
04:01 pm
fate
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
Medium
Report
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
11/9
01:30 pm
fate
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
Medium
Report
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
11/8
04:01 pm
fate
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
Medium
Report
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
11/4
04:01 pm
fate
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
10/2
04:01 pm
fate
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
9/19
08:00 am
fate
Kaskela Law LLC Announces Shareholder Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Shareholders to Contact the Firm
Low
Report
Kaskela Law LLC Announces Shareholder Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Shareholders to Contact the Firm
9/12
04:01 pm
fate
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
Medium
Report
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
9/12
12:57 pm
fate
Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report? [Yahoo! Finance]
8/22
08:33 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
8/22
07:34 am
fate
Broker Revenue Forecasts For Fate Therapeutics, Inc. (NASDAQ:FATE) Are Surging Higher [Yahoo! Finance]
Medium
Report
Broker Revenue Forecasts For Fate Therapeutics, Inc. (NASDAQ:FATE) Are Surging Higher [Yahoo! Finance]